Max Hospital, Noida, India.
Department of Dermatology and STD, VMMC and Safdarjung Hospital, Delhi, India.
J Cosmet Dermatol. 2021 Oct;20(10):3181-3189. doi: 10.1111/jocd.14251. Epub 2021 Jun 18.
Periocular melanosis (POM) due to shadow effect of tear trough deformity (TT) does not respond to the conventional treatment modalities. Hyaluronic acid (HA) fillers are a favurable treatment modality. This area is a high risk for injectables due to its unique anatomy.
To find role of HA fillers in treatment POM due to TT deformity with special emphasis on practical anatomy, patient satisfaction rate, and management of complications. A correlation of the grade of TT, age of the patient, and patient satisfaction was done. A follow-up at 1 year was done to assess longevity of results.
Retrospective study of 60 cases of clinically diagnosed POM (120 TT) due to TT deformity was performed. Each patient was injected with 1 ml, cross-linked HA 22.5 mg/ml in under-eye area using 30 G needle or a 25 G cannula. Follow-up was done at 2 weeks, 4 weeks, and 1 year.
Mean age of patients was 36.4 years. Majority of patients, that is, 31 (52%) were in the age group of 30-40. As per Hirmand's classification, 46.6% (28/60) had grade 2 TT which was most common. We graded results in the form of VAS and 80% patients had VAS > 7. There were no major side effects.
Hyaluronic acid fillers are promising treatment modality without any major side effects. Both needle and cannula can be used effectively. Patient satisfaction is higher in younger patients with low grade of TT and results persisted in all cases for a minimum of 1 year.
由于泪槽畸形(TT)的阴影效应导致的眶周黑色素沉着(POM)对常规治疗方法没有反应。透明质酸(HA)填充剂是一种受欢迎的治疗方法。由于其独特的解剖结构,该区域是注射剂的高风险区域。
寻找 HA 填充剂在治疗 TT 畸形引起的 POM 的作用,特别强调实用解剖学、患者满意度和并发症管理。对 TT 分级、患者年龄和患者满意度进行了相关性分析。对 1 年的随访进行了评估,以评估结果的持久性。
对 60 例临床诊断为 TT 畸形引起的 POM(120 例 TT)患者进行回顾性研究。每位患者均使用 30 G 针或 25 G 套管在下眼区域注射 1 ml、交联 22.5 mg/ml 的 HA。在 2 周、4 周和 1 年时进行随访。
患者的平均年龄为 36.4 岁。大多数患者(即 31 例,占 52%)年龄在 30-40 岁之间。根据 Hirmand 的分类,46.6%(28/60)的患者 TT 分级为 2 级,这是最常见的。我们采用 VAS 评分对结果进行分级,80%的患者 VAS>7。没有出现严重的副作用。
HA 填充剂是一种无明显副作用的有前途的治疗方法。针和套管均可有效使用。年轻患者、TT 分级较低且患者满意度较高的患者的效果持续时间至少为 1 年。